AI Oncology Leader RISA Labs Secures $11.1 Million to Revolutionize Cancer Care
January 15, 2026, 10:41 am
RISA Labs, an AI pioneer in oncology, secured $11.1 million in Series A funding. The investment fuels national deployment of its AI operating system. This system targets critical administrative hurdles: patient access, benefits verification, and prior authorization. It frees administrative staff, slashes denial rates, and dramatically accelerates treatment initiation. Co-led by Cencora Ventures and Optum Ventures, the capital will scale solutions across cancer clinics, health systems, and specialty pharmacies. RISA Labs aims to redefine oncology operations. Patients will access vital therapies faster. Clinical teams will focus on patient care, not paperwork. This marks a pivotal advancement in healthcare AI efficiency.
A new era in cancer care is dawning. RISA Labs, an innovator in artificial intelligence, has secured significant funding. The company announced an $11.1 million Series A round. This capital injection will propel its AI operating system across the United States. Its mission: to transform oncology workflows.
The financing round saw strong backing. Cencora Ventures and Optum Ventures co-led the investment. Oncology Ventures, Z21 Ventures, and John Simon also participated. This robust support underscores confidence in RISA Labs' vision. It confirms the urgent need for its technology.
RISA Labs addresses a critical pain point in modern healthcare. Cancer treatment is complex. Administrative tasks often create major bottlenecks. Patient access, benefits verification, and prior authorization consume immense resources. These delays impact patient outcomes. They burden already stretched healthcare staff.
RISA's platform acts as an intelligent automation layer. It streamlines these time-consuming administrative steps. The system connects directly to electronic medical records. It integrates with payer and benefits systems. This comprehensive connectivity enables seamless data flow.
At the core of RISA's solution are advanced AI agents. These agents tirelessly gather required information. They prepare complex submissions. They track authorization statuses. They advance cases across diverse payer environments. This proactive approach eliminates manual backlogs. It ensures continuous progress for each patient.
The AI agents possess a crucial capability: adaptability. Payer forms, rules, and interfaces constantly change. RISA's system adjusts in real time. It requires no continuous reprogramming. This ensures consistent workflow reliability. It prevents system obsolescence.
The flagship product is BOSS Console. RISA describes it as a central control panel. Institutions configure workflow routing. They set documentation conventions. They define practice-specific rules. BOSS Console provides full traceability. This ensures compliance and audit readiness. It makes every AI action transparent.
The system is purpose-built for oncology's unique demands. Cancer care involves multi-drug regimens. It navigates disease-specific requirements. Payer policies often vary widely. BOSS Console handles this operational complexity with precision. It reduces the margin for error.
Early deployments showcase dramatic improvements. RISA Labs' technology is already live. Leading oncology practices across the U.S. utilize it. Performance metrics from a partner site reveal impressive results. Administrative staff time saw roughly an 80% reduction. This frees personnel for higher-value work.
Denial rates plummeted by up to 40%. First-pass approval rates soared to 97.8%. These figures highlight significant financial and operational gains. They reflect a smoother, more efficient process. Patients gain faster access to vital therapies.
Authorization times improved drastically. Requests are now filed within 24 hours. The goal is to drop below two hours. This contrasts sharply with an average eight-day backlog. Such speed benefits patients facing time-sensitive treatments. It reduces anxiety and uncertainty.
The efficiency gains translate into workforce optimization. Over 20 full-time equivalent positions were repurposed. Staff shifted to clinical or operational priorities. This maximizes human capital. It allows practices to serve more patients. It enhances overall care quality.
The platform has already orchestrated significant value. In nine months, it managed access and authorization workflows. Over $400 million in oncology medications and infusion therapies were processed. This demonstrates substantial operational impact. It solidifies RISA's role in high-stakes healthcare.
The newly secured funding targets nationwide expansion. RISA Labs plans to broaden deployments. Cancer centers, health systems, specialty pharmacies, and infusion networks are key targets. This widespread adoption will redefine oncology operations nationally. From patient intake to infusion, efficiency will prevail.
RISA Labs envisions a future where clinicians focus on what matters most. Clinical judgment and patient care become paramount. The administrative burden shifts to intelligent automation. This addresses the "core mathematical problem" of modern oncology. Rising cancer incidence and complex protocols demand innovative solutions.
The company's strategic roadmap includes deepening its oncology footprint. RISA Labs will partner with ecosystem leaders. The aim is to extend AI-driven workflows across the full continuum of cancer care. This holistic approach ensures end-to-end optimization.
Specialty pharmacy operations represent a near-term expansion area. The same AI OS foundation will support this growth. BOSS Console will configure these new workflows. This signals a broader ambition for RISA Labs. They aim to redefine how complex care delivery systems operate in an AI-driven world.
This investment is more than financial. It is a commitment to transforming cancer care. It empowers healthcare providers. It expedites patient access to critical treatments. RISA Labs is not just building software. It is building capacity. It is building a better future for oncology.
A new era in cancer care is dawning. RISA Labs, an innovator in artificial intelligence, has secured significant funding. The company announced an $11.1 million Series A round. This capital injection will propel its AI operating system across the United States. Its mission: to transform oncology workflows.
The financing round saw strong backing. Cencora Ventures and Optum Ventures co-led the investment. Oncology Ventures, Z21 Ventures, and John Simon also participated. This robust support underscores confidence in RISA Labs' vision. It confirms the urgent need for its technology.
RISA Labs addresses a critical pain point in modern healthcare. Cancer treatment is complex. Administrative tasks often create major bottlenecks. Patient access, benefits verification, and prior authorization consume immense resources. These delays impact patient outcomes. They burden already stretched healthcare staff.
RISA's platform acts as an intelligent automation layer. It streamlines these time-consuming administrative steps. The system connects directly to electronic medical records. It integrates with payer and benefits systems. This comprehensive connectivity enables seamless data flow.
At the core of RISA's solution are advanced AI agents. These agents tirelessly gather required information. They prepare complex submissions. They track authorization statuses. They advance cases across diverse payer environments. This proactive approach eliminates manual backlogs. It ensures continuous progress for each patient.
The AI agents possess a crucial capability: adaptability. Payer forms, rules, and interfaces constantly change. RISA's system adjusts in real time. It requires no continuous reprogramming. This ensures consistent workflow reliability. It prevents system obsolescence.
The flagship product is BOSS Console. RISA describes it as a central control panel. Institutions configure workflow routing. They set documentation conventions. They define practice-specific rules. BOSS Console provides full traceability. This ensures compliance and audit readiness. It makes every AI action transparent.
The system is purpose-built for oncology's unique demands. Cancer care involves multi-drug regimens. It navigates disease-specific requirements. Payer policies often vary widely. BOSS Console handles this operational complexity with precision. It reduces the margin for error.
Early deployments showcase dramatic improvements. RISA Labs' technology is already live. Leading oncology practices across the U.S. utilize it. Performance metrics from a partner site reveal impressive results. Administrative staff time saw roughly an 80% reduction. This frees personnel for higher-value work.
Denial rates plummeted by up to 40%. First-pass approval rates soared to 97.8%. These figures highlight significant financial and operational gains. They reflect a smoother, more efficient process. Patients gain faster access to vital therapies.
Authorization times improved drastically. Requests are now filed within 24 hours. The goal is to drop below two hours. This contrasts sharply with an average eight-day backlog. Such speed benefits patients facing time-sensitive treatments. It reduces anxiety and uncertainty.
The efficiency gains translate into workforce optimization. Over 20 full-time equivalent positions were repurposed. Staff shifted to clinical or operational priorities. This maximizes human capital. It allows practices to serve more patients. It enhances overall care quality.
The platform has already orchestrated significant value. In nine months, it managed access and authorization workflows. Over $400 million in oncology medications and infusion therapies were processed. This demonstrates substantial operational impact. It solidifies RISA's role in high-stakes healthcare.
The newly secured funding targets nationwide expansion. RISA Labs plans to broaden deployments. Cancer centers, health systems, specialty pharmacies, and infusion networks are key targets. This widespread adoption will redefine oncology operations nationally. From patient intake to infusion, efficiency will prevail.
RISA Labs envisions a future where clinicians focus on what matters most. Clinical judgment and patient care become paramount. The administrative burden shifts to intelligent automation. This addresses the "core mathematical problem" of modern oncology. Rising cancer incidence and complex protocols demand innovative solutions.
The company's strategic roadmap includes deepening its oncology footprint. RISA Labs will partner with ecosystem leaders. The aim is to extend AI-driven workflows across the full continuum of cancer care. This holistic approach ensures end-to-end optimization.
Specialty pharmacy operations represent a near-term expansion area. The same AI OS foundation will support this growth. BOSS Console will configure these new workflows. This signals a broader ambition for RISA Labs. They aim to redefine how complex care delivery systems operate in an AI-driven world.
This investment is more than financial. It is a commitment to transforming cancer care. It empowers healthcare providers. It expedites patient access to critical treatments. RISA Labs is not just building software. It is building capacity. It is building a better future for oncology.